Table 1 Patients’ characteristics according to the ELN2022 genetic risk at diagnosis (n = 522).

From: Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation

 

All patients n = 522

ELN22 favorable n = 114

ELN22 intermediate n = 137

ELN22 adverse n = 271

P

Sex, n (%)

    

0.24

 male

261

54 (47)

62 (45)

145 (54)

 

 female

261

60 (53)

75 (55)

126 (46)

 

Disease origin, n (%)

    

<0.001

 secondary/treatment related

177

19 (17)

26 (19)

132 (49)

 

 de novo

345

95 (83)

111 (81)

139 (51)

 

Hemoglobin, g/dL

    

0.13

 median (range)

8.5 (3.4–14.9)

8.5 (3.8–14.7)

9 (3.4–5.6)

8.4 (4.2–14.9)

 

Platelet count, x 109/L

    

0.08

 median (range)

60 (1–950)

80 (3–442)

63 (7–289)

49 (1–950)

 

WBC, x 109/L

    

<0.001

 median (range)

6.4 (0.1–385)

18.6 (1–366)

13.6 (0.6–385)

3.6 (0.1–238)

 

Blood blasts, %

    

<0.001

 median (range)

23 (0–97)

32 (0–97)

42 (0–97)

14 (0–88)

 

Bone marrow blasts, %

    

<0.001

 median (range)

50 (0–99)

50 (14–100)

75 (21–99)

40 (0–95)

 

CD34+/CD38- cell burden

    

<0.001

 median (range)

0.7 (0–75)

0.1 (0–20.6)

0.5 (0–32.5)

2.1 (0–75)

 

LDH, ukat/l

    

0.34

 median (range)

6.12 (1.4–30.0)

7.1 (2.9–30.0)

8.6 (2.5–30.0)

5.2 (1.4–30.0)

 

RDW, %

    

0.02

 median (range)

16.1 (12.2–29.6)

16.1 (13.3–24)

16.2 (12.4–25.2)

17.1 (12.2–29.6)

 

Normal karyotype, n (%)

    

<0.001

 absent

182

48 (44)

48 (36)

233 (86)

 

 present

329

60 (56)

85 (64)

37 (14)

 

DNMT3A mutation, n (%)

    

0.002

 wild type

200

44 (65)

54 (67)

102 (84)

 

 mutated

70

24 (35)

27 (33)

19 (16)

 

FLT3-TKD mutation, n (%)

    

0.007

 wild type

391

82 (82)

107 (88)

202 (94)

 

 mutated

47

18 (18)

15 (12)

14 (6)

 

KIT mutation, n (%)

    

0.004

 wild type

183

43 (86)

49 (100)

91 (97)

 

 mutated

10

7 (14)

0 (0)

3 (3)

 

JAK2 mutation, n (%)

    

0.04

 wild type

144

29 (100)

39 (93)

76 (85)

 

 mutated

16

0 (0)

3 (7)

13 (15)

 

TET2 mutation, n (%)

    

<0.001

 wild type

143

21 (75)

48 (98)

74 (75)

 

 mutated

33

7 (25)

1 (2)

25 (25)

 

WT1 mutation, n (%)

    

0.02

 wild type

124

23 (96)

33 (87)

68 (99)

 

 mutated

7

1 (4)

5 (13)

1 (1)

 

Age at HSCT, years

    

<0.001

 median (range)

59.1 (16.3–76.4)

56.3 (16.3–76.4)

56.3 (19.4–75.9)

61.5 (20.3–76.2)

 

Remission status at HSCT, n (%)

    

<0.001

 CR/CRi

409

106 (93)

118 (86)

185 (68)

MRDpos vs MRDneg

 CR/CRi, MRDneg

166

35 (33)

39 (28)

53 (20)

 CR/CRi, MRDpos

102

34 (32)

34 (25)

34 (13)

0.40

 CR/CRi, no MRD information

141

37 (35)

45 (33)

98 (36)

 CR/CRi1

337

81 (76)

90 (76)

166 (90)

CR/CRi1 vs CR/CRi2

0.003

 CR/CRi2

70

24 (23)

27 (23)

19 (10)

 CR/CRi3

2

1 (1)

1 (81)

0 (0)

 PR/relapsed/refractory

113

8 (7)

19 (14)

86 (32)

 

Conditioning regimen, n (%)

     

 NMA

261

59 (52)

65 (47)

137 (51)

0.77

 RIC

120

12 (11)

26 (19)

82 (30)

<0.001

 MAC

141

43 (38)

46 (34)

52 (19)

<0.001

HCT-CI Score, n (%)

     

 0

203

63 (58)

43 (33)

97 (39)

<0.001

 1/2

157

26 (24)

52 (40)

79 (32)

0.03

 ≥ 3

134

20 (18)

35 (27)

74 (30)

0.08

Donor type, n (%)

     

 matched related

88

28 (25)

23 (17)

37 (14)

0.05

 unrelated, HLA matched

334

67 (59)

90 (66)

177 (66)

0.41

 HLA mismatched

96

17 (15)

19 (14)

50 (19)

0.46

 haploidentical

13

2 (2)

5 (4)

6 (2)

0.66

Donor sex, n (%)

    

0.49

 female into male

69

19 (17)

17 (13)

33 (12)

 

 all others

445

93 (83)

119 (88)

233 (88)

 

CMV status, n (%)

    

0.14

 recipient+/ donor –

187

42 (38)

38 (28)

99 (37)

 

 all others

339

70 (63)

99 (72)

170 (63)

 

Acute GvHD ≥ grade 2, n (%)

    

0.36

 absent

340

71 (73)

84 (71)

184 (78)

 

 present

113

26 (27)

34 (29)

53 (22)

 

Chronic GvHD, n (%)

     

 absent

165

36 (43)

41 (44)

88 (53)

0.20

 limited

50

13 (16)

21 (22)

16 (10)

<0.001

 extended

127

34 (41)

32 (34)

61 (37)

0.65

  1. CMV cytomegalovirus, CR complete remission, CRi complete remission with incomplete peripheral recovery, DNMT3A DNA methyltransferase 3 alpha gene, ELN European LeukemiaNet, FLT3 fms-like tyrosine kinase, FLT3-ITD internal tandem duplication of the FLT3 gene, FLT3-TKD tyrosine kinase mutations in the FLT3 gene, GvHD graft-versus-host disease, Hb hemoglobin, HLA human leukocyte antigen, HCT-CI hematopietic cell transplantation comorbidity index, HSCT hematopoietic stem cell transplantation, JAK2 Janus kinase 2 gene, LDH lactate dehydrogenase, MRD measurable residual disease, PB peripheral blood, PR partial remission, RDW red cell distribution width, TET2 Tet methylcytosine dioxygenase 2 gene, WBC white blood count, WT1 Wilm’s tumor gene 1.
Back to article page